Compare Johnson & Johnson (JNJ) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Zeta Global Holdings Corp — how do they compare? Johnson & Johnson trades at $250 (market cap $598.96B), while Zeta Global Holdings Corp trades at $21.72 (market cap $5.32B). The key difference: Johnson & Johnson is far larger — about 112.6× Zeta Global Holdings Corp's market cap, and Johnson & Johnson pays a 2.15% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals.
| JNJ | ZETA | |
|---|---|---|
Market Cap | $598.96B | $5.32B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $25.24 |
52-Week Low | $164.36 | $14.55 |
Enterprise Value | $631.90B | $5.23B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
ZETA trades at $21.34, down 1.57% on the day, with a bullish technical signal from moving averages and strong analyst support (73% buy ratings). The company reported Q1 2026 earnings of $0.14 per share, beating estimates, and is pivoting toward AI infrastructure through partnerships with Palantir and OpenAI. Revenue grew to $1.30 billion in 2025, though net income remained negative at -$31.51 million.
The outlook is positive due to AI-driven growth and strategic partnerships, but risks include margin pressure and integration challenges. The consensus price target of $27.50 suggests significant upside potential if execution aligns with bullish expectations, though negative profitability metrics warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
